Why the study?
Do cardioprotective modalities and early hypertension management reduce anthracycline-induced cardiotoxicity in cancer patients with hypertension?
Population
Cancer patients with hypertension receiving anthracycline chemotherapy
Design
Review
Authors
Loading...
May warrant early BP monitoring in anthracycline recipients; leaves open prospective validation of cardioprotective strategies.
Do cardioprotective modalities and early hypertension management reduce anthracycline-induced cardiotoxicity in cancer patients with hypertension?
Hypertension exacerbates anthracycline-induced cardiotoxicity, highlighting the need for early hypertension management and cardioprotective strategies in cancer patients.
Kuriakose et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: